A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine

Name: A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine
Published: 2023
License: Public Domain

Immorna Biotherapeutics, Inc. · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

infectious-disease mrna-vaccine

covid-19, infectious disease, mrna vaccine, covid vaccination, healthy subjects, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine

Related documents